Inogen (INGN) has provided an announcement.
Inogen, Inc. is set to part ways with Dr. Stanislav Glezer, their Executive Vice President of R&D and Chief Medical Officer, by May 3, 2024. The departure is a mutual decision, and Dr. Glezer is expected to receive benefits aligned with his existing employment and severance agreement. Details of the separation will be disclosed in a future filing with the Securities and Exchange Commission.
For an in-depth examination of INGN stock, go to TipRanks’ Stock Analysis page.
